Biocryst Pharmaceuticals reported $38.02M in Selling and Administration Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
DBV Technologies DBVT:US 5.28M 1.22M
Alnylam Pharmaceuticals ALNY:US $ 169.98M 15.51M
Biocryst Pharmaceuticals BCRX:US $ 38.02M 3.74M
Chemocentryx CCXI:US $ 28.18M 2.17M
Chugai Pharma 4519:JP 22.03B 3.23B
Daiichi Sankyo 4568:JP 96.37B 8.36B
Enanta Pharmaceuticals ENTA:US $ 12.93M 2.45M
Gilead Sciences GILD:US $ 1.36B 274M
GlaxoSmithKline GSK:LN 195.5B 18.5B
Glaxosmithkline GSK:US 1.96B 726M
Intra Cellular Therapies ITCI:US $ 100.32M 24.86M
IONIS PHARMACEUT IONS:US $ 33.8M 325K
Karyopharm Therapeutics KPTI:US $ 37.34M 1.43M
Mirati Therapeutics MRTX:US $ 54.23M 277K
Neurocrine Biosciences NBIX:US $ 182.8M 17.9M
Novavax NVAX:US $ 108.16M 12.17M
Ptc Therapeutics PTCT:US $ 79.89M 6.62M
Regeneron Pharmaceuticals REGN:US $ 476.3M 26.3M
Sarepta Therapeutics SRPT:US $ 154.32M 82.48M
Ultragenyx Pharmaceutical RARE:US $ 68.14M 825K
Vertex Pharmaceuticals VRTX:US $ 215.3M 100K
YTE INCY:US $ 253.28M 43.69M